InvestorsHub Logo
Followers 5
Posts 721
Boards Moderated 0
Alias Born 10/17/2007

Re: Porgie Tirebiter post# 80928

Sunday, 02/01/2009 2:09:03 PM

Sunday, February 01, 2009 2:09:03 PM

Post# of 82595
"Porgie Tirebiter,"

This statement you made is incorrect, and appears to be based on an outdated outstanding share count: "With today's share price, total market cap is still about one thirteenth of what we know this company owes to creditors."

I have yet to see an online service, that updates outstanding share count correctly. The generally accepted procedure is to call the registrar, for current share count, and not trust what the online services display, for that figure.

When I last called the registrar, on 1/28/2008, DNAG's outstanding share count was:
1,294,790,465 (unchanged since at least 11/17/2008)
Authorized share count remained unchanged, also:
1,500,000,000

Using current share count, at Friday's closing price of .0013, market cap is a little over $1.68M. Multiply that by 13 (to check your scenario) and the result is around $22M. I have seen no estimate that claims their debt is so high; the estimates I've seen have all been much closer to $10M, so instead of 1/13th, the actual number is probably much closer to 1/6th. As we know, DNAG market cap has increased considerably, in recent months. I would not be surprised to see DNAG's market cap surge past $10M, or even $100M, relatively quickly.

Registrar contact information:

Standard Registrar & Transfer
12528 S 1840 E, Draper, UT 84020-9100, United States
Phone: (801) 571-8844

As it becomes obvious to more investors, that DNAPrint Genomics and all of its assets (including intellectual property) is actually worth, with funding, far more than than what it owes to creditors, it makes sense that investors would be attracted, and securing new funding for DNAG becomes something that is much more likely. As I consider DNAG to be worth far more than $10M, I think that, for DNAG to not obtain funding, would represent a major missed investment opportunity. I also think that, if/when DNAG secures new funding (or income becomes sufficient to negate the need for additional funding,) share price would appreciate very dramatically.

Aside from the numbers I stated above, these statements are my opinions only, of course, but I think they are reasonable.

Daniel